Search Results

Nuvalent, Inc. announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 4:30 p.m. ET in NYC.

Nuvalent, Inc. (Nasdaq: NUVL) today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) to NVL-655 for the treatment of patients with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) who have been previously treated with two or more ALK tyrosine kinase inhibitors (TKIs).

Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, highlighted pipeline progress, reiterated key anticipated milestones, and reported first quarter 2024 financial results.

Nuvalent, Inc. announced its “OnTarget 2026" operating plan to guide efforts towards having its first potential approved product in 2026.

Nuvalent, Inc. announced that the U.S. Food and Drug Administration has granted breakthrough therapy designation to NVL-520 for the treatment of patients with ROS1-positive metastatic non-small cell lung cancer who have been previously treated with two or more ROS1 tyrosine kinase inhibitors.

Nuvalent, Inc. (Nasdaq: NUVL) today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024, at 10:30 a.m. ET in NYC.

Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, highlighted pipeline progress, reiterated key anticipated milestones and reported fourth quarter and full year 2023 financial results.

Nuvalent, Inc. (Nasdaq: NUVL) today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 7:30 a.m. PT in San Francisco.

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the presentation of new preclinical data for its novel HER2-selective inhibitor, NVL-330, and novel ROS1-selective inhibitor, zidesamtinib (NVL-520).

Nuvalent, Inc. announced that it has commenced an underwritten public offering of $300.0 million of its shares of Class A common stock.